Drug intelligence / Profile preview

MT963

Development stage
Unknown
Lead developer
Medytox
Modality
Small Molecules
01

Overview

MT963 is a health supplement developed by Medytox, specifically formulated as a hangover cure and liver health support product. Marketed under the brand name Kandol (칸돌) through its subsidiary Medy Bloom, it is classified as a health functional food (HFF) in South Korea. The formulation is a combination of active ingredients including glutathione, which facilitates the metabolism of acetaldehyde (the primary toxic metabolite of alcohol), and milk thistle extract (silymarin), which provides hepatoprotective effects by stabilizing liver cell membranes and reducing oxidative stress. Additionally, it incorporates a complex of B-vitamins (B1, B2, B6), Vitamin C, and taurine to support energy metabolism and mitigate fatigue associated with alcohol consumption. MT963 is designed to accelerate the detoxification process and protect hepatocytes from alcohol-induced damage.

Brand names
Kandol
Other names
Candol칸돌
02

Targets

GSH (Glutathione synthesis / redox)ALDH1A1 (Aldehyde dehydrogenase 1 family member A1)ADH (Alcohol dehydrogenase family)

Beyond the preview

Go deeper on MT963.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on MT963.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call